ARCHIVES

Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial

This article is from The Cancer Letter archive.

Vol. 35 No. 1 | January 27, 2012

Download PDF Visit The Full Archive

Related Articles

Rall, FDA Chief On AACR Panel

April 27, 1979

NCAB Members Flay NIH Proposals To Kill Cancer Program, Strip Board An NCI Of Special Authority

January 25, 1980

In Brief: NCI Reorganization Announcement Coming Up; No Decisions On Organ Site, Center Programs NCI Reorganization

May 12, 1978

NCCS Networker Volume 3 Issue 1, Winter 1989

January 13, 1989

Rep. Bliley Challenges FDA On Failure To Approve Oral Colon Cancer Drug UFT.

April 21, 2000

Two-Week Break Balances RT Palliation, Side Effects

February 26, 2010